Sanofi Pasteur’s Quadrivalent Flu Vaccine Succeeds in Phase III Pediatric Study

Trial compared QIV with trivalent vaccines in children aged 6 months to 8 years.

Heat Biologics Hosts Groundbreaking Ceremony for Biomanufacturing Facility

The company’s platform is designed to activate immune responses against cancer and infectious diseases.

Could Zika Virus Be Developed to Treat Glioblastoma?

Scientists have used modified strains of Zika virus to kill glioblastoma stem cells in cancer-bearing mice, and prolong their lifespan

Can CUT&RUN and CUT&Tag Replace ChIP-Seq?

CUT&RUN and CUT&Tag assays are dramatically changing how scientists perform chromatin mapping experiments by providing high-quality data using low cell inputs and sequencing depths. Some have speculated that these novel strategies will render the standard ChIP-seq assay obsolete in the next decade. The result of CUT&RUN and CUT&Tag assays, enabled by EpiCypher’s CUTANA™ platform, is highly efficient and streamlined isolation of target fragments for ultra-sensitive chromatin mapping.

Aromatherapy Wafts toward Drug Discovery Space

Contrary to generally held belief, most essential oil components are amenable to medicinal chemistry techniques and may qualify as good drug candidates, report scientists based at VIB-KU Leuven. Moreover, these components also offer attractive opportunities for lead optimization or even fragment-based drug discovery. Because their therapeutic potential is still under-scrutinized, the scientists propose that essential oil components be explored more vigorously with present-day methods.

3D Model of Alzheimer’s Shows Role of Blood-Brain Barrier in Disease...

MIT engineers have now developed a tissue model that mimics beta-amyloid's effects on the blood-brain barrier, and used it to show that this damage can lead molecules such as thrombin, a clotting factor normally found in the bloodstream, to enter the brain and cause additional damage to Alzheimer's neurons.

Pfizer, OPKO Partner to Advance GHD Treatment in $570M+ Deal

Pfizer is partially funding OPKO Health’s hGH-CTP development and commercialization initiatives in a deal that is potentially worth more than $570 million.

Universal Flu Vaccine a Nanoparticle That Is All Stalk, No Head

Nanoparticle vaccine stabilizes headless stalks, protects mice against divergent flu viruses

Successful Passage: Gene Therapy Shows Early Effectiveness in GM1

Philadelphia-based Passage Bio develops gene therapies for rare, monogenic CNS disorders through a strategic collaboration and licensing agreement with the University of Pennsylvania’s Gene Therapy Program (GTP) to conduct discovery and IND-enabling preclinical work. A year after it was launched in 2019, the company went public through an initial public offering that raised $227.5 million. Passage Bio’s co-founders include GTP Director and gene therapy pioneer James M. Wilson, MD, PhD.

Novel Mechanism Targets “Undruggable” RAS Oncogenes

Researchers have identified a new mechanism for targeting an important cancer gene.